CHAPTER N0.

27

From Insulin Resistance to Beta Cell Failure: Exploring the Pathophysiology and Management of Diabetes

QURAT UL AIN IQBAL[1*], FARIA MUSHTAQ[1], HIRA IQBAL[1], HAFSA IHSAN[1], MINAHIL FATIMA KHILJI[1], LAIBA IBRAR[1], BAHADUR SHAH BUKHARI[1], HUSSAIN ABBAS[1]

[1]Akhtar Saeed College of Pharmacy, Rawalpindi, Pakistan
[*]Corresponding author: quratulain.iqbal04@gmail.com

ABSTRACT: The disease "Diabetes Mellitus" is a disorder of metabolism that is very common and chronic, which is affecting a major population of the world. It poses a significant challenge to our healthcare systems. This disease occurs when there is an abnormal functioning of the hormone insulin, which is secreted from beta cells in the islets of Langerhans. When there is a problem with insulin, this disease results. Not enough insulin production and when insulin is not working properly or can be due to when both happen which ultimately results in high blood glucose levels in the body which is serious and alarming. The variations of diabetes mellitus can be categorized by 4 major types. Type 1 Diabetes mellitus addresses autoimmune dysfunction of beta cells, whereas type 2 Diabetes mellitus happens due to insulin resistance. Other categories are Gestational Diabetes that happens during pregnancy and other neonatal and monogenic diabetes. The etiological aspects of this disease can be genetic factors, lifestyle and environmental factors, obesity, metabolic dysfunction, and endocrine disorders. They may all result in this disease. The pathophysiology depends on major mechanisms that are insulin resistance, beta-cell dysfunction, glucotoxicity, lipotoxicity and inflammation, and other genetic and environmental factors. This disorder is indeed serious, but it can be treated and managed with lifestyle and behavioral interventions, but majorly pharmacological therapy is needed that may include ant glycemic agents, insulin therapy, emerging and novel therapies, technology, monitoring, self-managements, and personalized and precision medicine. Other novel strategies are also introduced to control its severity and complications. Major if dietary management is balanced and prioritized, then we can manage this progressive disease. To lessen the burden of disease and avoid complications, this integrates current knowledge on epidemiology, mechanistic pathways, risk factors, and therapeutic approaches, highlighting the necessity of integrated care models, patient education, and early metabolic stabilization.

Keywords: Diabetes mellitus, Insulin resistance, Hyperglycemia, Pathophysiology, Management, Novel therapies

INTRODUCTION

Diabetes mellitus is derived from the Latin term mellitus, which means sweet, and the Greek word diabetes, which means siphon—to pass through. According to a historical analysis, Apollonius of Memphis coined the name "diabetes" sometime between 250 and 300 BC. The term "diabetes mellitus" originated when ancient Greek, Indian, and Egyptian societies noticed the sweetness of urine with this illness. In 1889, Mering and Minkowski identified how the pancreas contributes to the pathophysiology of diabetes. At the University of Toronto, Banting, Best, and Collip isolated the hormone insulin from cow pancreas in 1922, which resulted in the development of a successful diabetic treatment. A better attempt has been made over the years to address this expanding issue, and many novel observations and management approaches have been developed. Regretfully, diabetes is still among the most prevalent chronic illnesses in the nation and around the world (Antar et al., 2023).

Persistent hyperglycemia is a defining feature of diabetes mellitus (DM), a chronic metabolic disease. Impaired insulin secretion, resistance to insulin peripheral effects, or both could be the cause. When combined with other metabolic abnormalities, chronic hyperglycemia in patients with diabetes mellitus can harm multiple organ systems and result in life-threatening and incapacitating health issues. The most common ones are microvascular (retinal vascular disease, nephrosis, and neural disorder) and major vessel related issues, which increase the risk of heart problems up to a major extent (Goyal R et al.,2023).

The islets of Langerhans are specialized cell clusters in the pancreas that produce the hormones glucagon and insulin. Insulin is secreted by beta (β) cells in these islets, whereas glucagon is released by alpha (α) cells. Insulin lowers blood glucose levels by encouraging the synthesis of glycogen and makes it easier for muscle, liver, and adipose tissues to absorb glucose. On the other hand, glucose is used by nerve tissue and erythrocytes without the need for insulin. Glycemic levels are raised by releasing glucagon by promoting the breakdown of glycogen; alpha cells are crucial for preserving glucose homeostasis. An alarming situation of excessive weight gain, metabolic and heart diseases, and cancer later in postnatal life is linked to disruptions in glucose regulation. Eighty to ninety

How to Cite: Iqbal QUA, F Mushtaq, H Iqbal, H Ihsan, MF Khilji, L Ibrar, BS Bukhari, H Abbas, 2025. From insulin resistance to beta cell failure: exploring the pathophysiology and management of diabetes. In: Advances in Pharmacology and Integrative Therapeutics (Aslam B, W Majeed, A Iftikhar, S Javed, I Abbas, Eds). FahumSci, Lahore, Pakistan, pp: 192-197. ISBN: 978-627-7745-13-4. https://doi.org/10.61748/APIT.2025/27

percent of cases of diabetes are type II diabetes mellitus. Disease prevalence, severity, and mortality rates are influenced by regional differences. Additionally, people with diabetes who engage in moderate physical activity have a much lower mortality risk than those who are sedentary. Current research also suggests that a particular genetic predisposition influences the onset of diabetes (Singh et al., 2016).

According to a 2014 World Health Organization assessment, 8.5% of adults over the age of 18 had diabetes. Nearly half (48%) of the 1.5 million deaths caused by the disease in 2019 happened to people under the age of 70. Additionally, diabetes indirectly contributed to about 460,000 deaths from complications related to the kidneys. Furthermore, about one-fifth (20%) of deaths from cardiovascular diseases were linked to elevated blood glucose. Nearly 20% of deaths associated with serious heart and vascular diseases were also linked to high blood sugar. Age-adjusted mortality rates specifically linked to diabetes increased by 3% worldwide between 2000 and 2019, demonstrating a consistent upward trend. In lower-middle-income nations, where diabetes-related mortality rates rose by 13%, the burden was even more severe. The four most common non-communicable diseases—diabetes, cancer, chronic respiratory conditions, and cardiovascular disorders—saw a significant decrease in overall premature mortality despite this increase. During the same period, there was a 22% decrease in the worldwide likelihood of dying from these conditions between the ages of 30 and 70. Even though diabetes alone continued to show rising mortality in several developing regions, this reduction highlights broader improvements in the protection and intervention of chronic disorders (Samar A et al., 2023).

It is now acknowledged that diabetes mellitus is an ailment that exhibits the "iceberg" phenomenon, which means that the vast number of unrecognized cases is much greater than the number of reported cases. Not enough β-cell-derived hormone production by the pancreas or inadequate insulin consumption by the body can cause this lifelong disorder. Uncontrolled diabetes often leads to high blood glucose, which, over time, causes significant harm to the body (Tegegne et al., 2024).

CATEGORIZATION OF DIABETES MELLITUS

Autoimmune β-cell Failure Diabetes

The hallmark of type 1 diabetes is leading to absolute insulin deficiency, which is an immune dysfunction of beta cell failure. The American Diabetes Association states that "your sugar levels are so high that your body is unable to synthesize insulin". The pancreatic cells that make insulin are attacked by an autoimmune process, which results in a total loss of insulin production. The physiological result is simple but dire: glucose from the metabolism of carbohydrates enters the bloodstream but is unable to enter cells for use as fuel. Consequently, glucose builds up in the blood, resulting in hyperglycemia and the characteristic symptoms of polyuria, polydipsia, and polyphagia, which are sometimes accompanied by unexplained weight loss despite increased appetite (Yameny, 2025).

Insulin-Resistant Diabetes

The most prevalent category that is affecting worldwide has a more complicated pathophysiological picture that includes both increasing beta cell failure and insulin resistance. In contrast to other forms of diabetes, insulin production persists, but its ability to regulate blood glucose levels declines. The illness usually progresses slowly and is frequently preceded by a prediabetic condition marked by poor glucose tolerance or poor fasting glucose. It is becoming more widely acknowledged that type 2 diabetes is "one component of metabolic syndrome" or what some researchers refer to as "metabolic dysfunction syndrome (MDS)" (Yameny, 2025).

Gestational Diabetes (GDM)

Pregnancy causes gestational diabetes, which usually disappears after giving birth to an infant, but greatly raises the chance of insulin-resistant diabetes in later life. This is brought on by insulin resistance brought on by pregnancy, as well as insufficient compensatory insulin secretion. As the body tries to prioritize nutrient supply to the developing fetus, hormonal changes during pregnancy, especially in the second and third trimesters, lead to insulin resistance. Careful control of gestational diabetes is necessary to avoid complications that might impact both mother and child, such as macrosomia, delivery trauma, and neonatal hypoglycemia (Yameny, A. 2025).

Other Types of Diabetes

Other than the more prevalent types, about 2% of cases of diabetes have different underlying causes. These include monogenic forms, like neonatal diabetes and Monogenic diabetes, which are caused by an alteration in one gene that affects insulin activity. Adult-onset autoimmune Diabetes, which combines both types, is another atypical form. Other conditions like pancreatic disorders, cystic fibrosis, or side effects from some medications, especially glucocorticoids and antipsychotics, can also lead to secondary diabetes. Furthermore, Wolfram syndrome and Alström syndrome are two uncommon inherited disorders that are known to have diabetes (Yameny, A. 2025).

PUBLIC HEALTH PROFILE OF DIABETES

In 2011, an estimated 366 million people had diabetes mellitus; by 2030, that number will have increased to 552 million. Every country is seeing a rise in the number of persons with type 2 diabetes, with 80% of those affected residing in low- and middle-income nations. In 2011, 4.6 million mortality incidents were attributed to DM. In the future, this disease is expected to impact 439 million individuals. Emergence of T2DM differs significantly between regional populations due to environmental and lifestyle-related risk patterns. In the coming time, it is anticipated that the occurrence of diabetes mellitus (DM) in adults, in which the prediction is that T2DM will be more common and will rise alarmingly. A major division of this growth is expected to take place in emerging nations, where many patients are middle-aged adults (Deshmukh et al., 2021)

Table 1. Etiological aspects of diabetes mellitus with key factors and mechanisms

Category	Key factors	Mechanism	References
Genetic factors	Family history of diabetes Gene polymorphism 3. Monogenic β-cell Defects	Genetic variations reduce insulin secretion, alter β-cell sensitivity, and predispose to insulin resistance.	Lu et al., 2024
Lifestyle and environmental factors	High-calorie diet Physical inactivity Chronic stress 4. Urbanization	Promote obesity and insulin resistance through lipid accumulation, oxidative stress and altered energy	
Obesity and Metabolic Dysregulation	Elevated TNF-α, IL-6, CRP Mitochondrial dysfunction	Adipokine imbalance and low-grade inflammation impair insulin signaling pathways	Sanyaolu et al., 2023
Endocrine and metabolic disorders	Polycystic ovary syndrome (PCOS) 2. Cushing's syndrome	Alter hormonal balance leading to secondary hyperglycemia and insulin resistance	

PATHOPHYSIOLOGY

When the delicate balance between insulin secretion and activity is upset, persistent hyperglycemia and the metabolic problems that accompany it result in diabetes mellitus (DM). Insulin resistance, which is a minimized outcome of marked tissues to insulin, with β-cell dysfunction, which gradually reduces insulin secretion, interacts dynamically in the central pathological features.

Major Mechanisms

Insulin resistance

Insulin signaling malfunctions in important metabolic tissues like the voluntary muscle, the liver, and fat tissue. As a result, muscles absorb less glucose; the liver produces more glucose, and adipose tissue releases more free fatty acids and adipokines. Insulin resistance is sustained by these changes, which also interfere with insulin signaling pathways (Alanazi et al., 2024).

β-cell dysfunction and decline

Initially, insulin secretion is increased by β-cells of the islets of Langerhans to compensate for insulin hindrance. But long-term metabolic stress, which is brought on by oxidative damage, lipotoxicity, glucotoxicity, and mitochondrial impairment, eventually results in β-cell exhaustion and apoptosis, which eventually reduces insulin production (Vybhavi et al., 2025).

Glucotoxicity and lipotoxicity

Long-term increases in blood glucose and free fatty acids are harmful to β-cells and insulin-sensitive tissues. These metabolic insults cause oxidative stress, endoplasmic reticulum stress, inflammatory signaling, and mitochondrial dysfunction, all of which worsen insulin resistance and hasten the degeneration of β-cells (Vybhavi et al., 2025).

Inflammation and adipokine imbalance

TNF-α and IL-6 are two cytokines that cause insulin sensitivity in chronic low-grade inflammation, which is mostly caused by excess adipose tissue. Concurrently, altered adipokine secretion (such as lower levels of adiponectin) deteriorates metabolic control and β-cell function (Prasetyo, 2025).

Genetic, epigenetic, and environmental factors

Genes like TCF7L2 and PPARG have variations that make people more vulnerable to insulin resistance and β-cell dysfunction. Epigenetic changes brought on by a sedentary lifestyle, diet, or intrauterine environment also affect the risk of disease. The pathophysiology of diabetes is also linked to exposure to environmental toxins, circadian rhythm disruption, and an imbalance in the gut microbial community (Vybhavi et al., 2025).

Progressive metabolic deterioration and complications

Many biochemical pathways, such as the polyol pathway, the production of advanced glycation end products (AGEs), the activation of protein kinase C, and the hexosamine flux, become overactive with prolonged hyperglycemia. Endothelial dysfunction, microvascular damage (retinopathy, nephropathy, neuropathy), and macrovascular problems like cardiovascular and cerebrovascular disorders are all brought on by these processes (Ohiagu et al., 2022).

DIAGNOSIS

Urine glucose testing, blood glucose measurement, glucose tolerance tests, renal glucose threshold assessment, and detection of altered glucose tolerance are some of the tests used to diagnose diabetes mellitus. Additional methods of diagnosis include identifying renal glycosuria, examining prolonged glucose tolerance curves, and conducting specialized tests like the oral, intravenous, and cortisone-stressed glucose tolerance tests. The following blood-based tests are frequently used to diagnose diabetes mellitus: Random Plasma Glucose Test: When random blood glucose levels are 11.1 mmol/L (200 mg/dL) or higher, especially in the presence of typical diabetes symptoms, diabetes can be diagnosed. Fasting Plasma Glucose (FPG) Test: When fasting blood glucose levels are 7.0 mmol/L (126 mg/dL) or higher on at least two different occasions, diabetes is diagnosed. Prediabetes is indicated by values between 100 and 125 mg/dL, whereas normal fasting plasma glucose levels should stay below 100 mg/dL. Test for sugar tolerance: This test examines blood sugar levels two hours after oral glucose intake to diagnose diabetes. Diabetes is confirmed by a two-hour plasma glucose level of 200 mg/dL or more; prediabetes is indicated by levels between 140 and 199 mg/dL. Postprandial Blood Glucose Test: Two hours following a meal, this test gauges blood glucose levels. These are for those kinds of individuals whose sugar levels are extremely high in

the blood. Diabetes is noticed by a postprandial glucose level of 200 mg/dL or higher (Singh et al., 2016).

TREATMENT AND MANAGEMENT OF DIABETES

Diabetes mellitus (DM) management is very necessary to control its severity and complications. Although it is a progressive disease, it can be managed and treated with proper life-changing habits. This disease should be properly looked after with two main managements, which are lifestyle, behavioral interventions and pharmacological therapy. Majorly, this disorder is treated with pharmacological therapy that includes drugs and other insulin delivery systems, along with novel strategies that have been introduced to make this disease treatable. The following are the major aspects of treating this disease.

Lifestyle and Behavioral Interventions

Lifestyle is very important for treating this disease. Everything in moderate quantity can lead to a well-balanced and properly managed diet. Focusing on whole grains, lean proteins, healthy fats, and an abundance of fruits and vegetables, a balanced diet is crucial, while keeping an eye on controlling portion sizes and consuming fewer carbohydrates to prevent blood sugar from rising. Walking, cycling, and swimming are examples of regular physical activity that improve insulin sensitivity and help with weight management, both of which are essential for managing Type 2 diabetes. For those who are overweight, losing weight can greatly improve blood sugar regulation and lower the need for prescription drugs. Additionally, since long-term stress can increase blood sugar levels, stress management practices like yoga, meditation, and mindfulness are crucial. Proper sleep is also very mandatory and regular medical check-ups for proper and efficient monitoring. Together, these actions increase pancreatic islet cell activity, improve insulin sensitivity, and may, in certain cases, postpone the need for pharmacologic therapy (Bharti and Sukhwant, 2025).

Pharmacological Therapy

Conventional Antihyperglycemic Agents

For type 2 diabetes mellitus (T2DM), metformin is still the first-line treatment unless it is contraindicated. Depending on glycemic targets, comorbid conditions, and unique patient characteristics, other pharmacologic classes, including sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists, are prescribed either alone or in combination (Bharti and Sukhwant, 2025).

Insulin therapy

For those with advanced insulin-producing cell failure, autoimmune diabetes, or acute metabolic decompensation, those people who can't maintain glycemic control with oral medications, insulin is still essential. To maintain strict but safe glucose control, current research supports earlier insulin initiation and individualized titration regimens (McGill et al., 2024).

Emerging and novel therapies

Dual GLP-1/GIP receptor agonists, dual SGLT1/2 inhibitors, and drugs that target cellular energy pathways (like AMPK activators) and metabolic dysfunction at the molecular level are examples of recent pharmacological developments. Beyond just lowering blood sugar, these innovative methods also improve cardiovascular, renal, and weight management (Gieroba et al., 2025).

Technology, monitoring and self-management

Diabetes care has changed because of the integration of digital health advancements, such as telemedicine platforms, self-regulating insulin delivery devices, and real-time glucose sensors. Recent advances are enabling real-time glucose monitoring, improved hypoglycemia prevention, and increased patient autonomy. To optimize results, the technology should be customized to the patient and education should continue (Yameny, 2025).

Complication prevention and comorbidity management

Effective management is something that goes beyond blood sugar control. Includes blood pressure control, lipid management, and renal protection. Drugs that have a significant beneficial effect on the heart and kidneys, regardless of their glucose effect. Examples are GLP-1 receptor agonists and SGLT2 inhibitors to minimize long-term morbidity; regular screening for microvascular complications should be conducted. (Wu et al., 2025).

Personalized and precision medicine

Recent research has shown that precision medicine is essential to manage diabetes efficiently. The management is customized based on interindividual differences in genetics and metabolism as well as on a person's personal phenotype, such as age, comorbidities, hypoglycemia risk, and obesity status. Prospective treatment choices may involve options such as gene therapy, immunomodulatory therapies, and β-cell preservation and regeneration, especially for early or atypical patients. Management of diabetes mellitus involves multiple approaches, including technology-based interventions, drug-based innovations, lifestyle optimization, and personalization of medical care. To achieve a glycemic control that is almost normal and to prevent complications, organ functions are to be preserved while the quality of life of the patient is improved (Bharti and Sukhwant, 2025).

EVIDENCE-BASED DIETARY PATTERNS FOR GLYCEMIC CONTROL

Research has identified several dietary patterns that are effective in improving blood glucose regulation and overall metabolic health in people with this disorder. The Mediterranean diet features fish and poultry in moderate portions. It consists of a higher intake of fruits, vegetables, unrefined cereals, legumes, nuts, and olive oil. This diet has

been repeatedly reported to improve lipid profiles, achieve better glycemic control, and decrease the cardiovascular disease risk of diabetic patients. The high amounts of dietary fiber, antioxidants and monounsaturated fats contained in it improve insulin sensitivity and decrease inflammation. A person's metabolic needs and preferences may affect dietary choice (Minari et al., 2023).

Different plant-based strategies focus on the consumption of fruits, vegetables, whole grains, legumes, seeds and nuts and limit or completely omit animal products. These are high-fibre and rich bioactive foods that regulate blood sugar and increase insulin sensitivity. Further, a study has shown that plant-based diets may help people control their weight better and reduce their risk of diabetes (Ansari et al., 2024).

According to studies, consuming fewer carbohydrate-rich foods, such as glucose and fructose, limits variations following a glucose meal. There is evidence that these diets lead to better glycemic outcomes, and patients on low-carb diets have lower HbA1c levels. Recent research shows the impact of low-carbohydrate diets on lowering HbAlc and adjustment of antidiabetic drug dosing. However, a restricted diabetes diet requires close monitoring to see whether nutrient requirements are met and whether the diet is followed in the long term (Accurso et al., 2008).

MODERN INSULIN DELIVERY SYSTEMS

Many devices have come up recently to ensure the most optimal possible glycemic control, with the aim of making insulin delivery easier and more accurate and efficient. Insulin syringes, pen injectors, inhaled insulin preparations, insulin pumps, implantable pumps and innovative others are designed to enhance patient compliance and metabolic outcome (Singh et al., 2016).

ORAL ANTIDIABETIC (HYPOGLYCEMIC) AGENTS

The therapeutic options for managing diabetes have greatly increased with the development of oral antidiabetic drugs. An early turning point in oral therapy was the introduction of the biguanide phenformin in 1957, along with sulfonylureas. Newer drug classes, including Glitazones, Glinides, α-glucosidase inhibitors, and more recently, Incretin enhancers, have been developed because of ongoing research. These classes offer additional mechanisms to improve glycemic control and minimize complications (Singh et al., 2016).

NOVEL STRATEGIES

One of the world's most significant public health issues is diabetes mellitus. Patients are typically treated with repeated daily subcutaneous insulin injections; however, these injections may result in local discomfort, patient noncompliance, hypoglycemia, inability to control glucose homeostasis, infections, and fat deposits at the injection sites. Many attempts have been undertaken in the past few years to create effective and safe nanoparticles for oral insulin administration. Although oral delivery is thought to be the most efficient substitute for insulin injection, there are several issues with enzymatic proteolysis, digestive breakdown, and absorption obstacles. Numerous inorganic, lipid-based, polymeric, and synthetic nanoparticles have been studied for potential use. Despite recent advancements in oral insulin delivery methods, further research is necessary before clinical trials are carried out (Abdel- Moneim and Ramadan, 2022).

CONCLUSION

In conclusion, millions of people worldwide suffer from the common and chronic metabolic disease known as diabetes mellitus. Diabetes can seriously impair quality of life if it is not properly managed. These complications can affect the heart, kidneys, eyes, nerves, and blood vessels. If you have recently been diagnosed with diabetes, managing your diabetes may seem difficult. Don't be alarmed; with proper care, it can be easily managed. Controlling blood glucose levels is key to diabetes care. In addition, the adoption of healthy lifestyle choices, including stress management, regular physical activity, a balanced diet, and ideal weight maintenance, can be beneficial. Most patients with diabetes, in addition to making lifestyle changes, will need medication and insulin therapy to keep blood sugar levels relatively normal and to prevent further damage from occurring. In addition to these, any diabetes treatment requires routine check-ups, blood sugar monitoring, and patient education. Early identification and a therapeutic approach are required for individuals requiring management for diabetes. There are better results for people. Individuals who are afflicted with an illness are conscious of it. Thus, they can identify symptoms early and get treatment from a doctor to avoid major damage. In addition, encouragement from medical staff, family, and the company of others further motivates patients to comply with treatment. When diagnosed and treated properly, diabetes can be easily controlled. With the help of ongoing medical attention, lifestyle alterations, and awareness, human beings can live an active and healthy life. Furthermore, preventive strategies and education are still important in reducing the growing burden of diabetes within society and improving individual health.

REFERENCES

Abdel-Moneim A and H Ramadan, 2022. Novel strategies to oral delivery of insulin: Current progress of nanocarriers for diabetes management. Drug Development Research

Accurso A, RK Bernstein, A Dahlqvist et al., 2008. Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutrition and metabolism 5:9.

Alanazi SM, SM Alasad, MMA Alqabi et al., 2024. Diabetes Mellitus: Pathophysiology, Insulin Resistance, Nutritional Care, and Nursing Implications. Journal of International Crisis and Risk Communication Research 7:33.

Ansari P, JT Khan, S Chowdhury et al., 2024. Plant-based diets and phytochemicals in the management of diabetes mellitus and prevention of its complications: A review. Nutrients 16:3709.

Antar SA, NA Ashour, M Sharaky et al., 2023. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomedicine and Pharmacotherapy 168:115734.

Deshmukh CD, A Jain and B Nahata, 2015. Diabetes mellitus: a review. Int. J. Pure Appl. Biosci, 3:224-30.

Gieroba B, A Kryska and A Sroka-Bartnicka, 2025. Type 2 diabetes mellitus–conventional therapies and future perspectives in innovative treatment. Biochemistry and Biophysics Reports 42:102037.

Goyal R, M Singhal and I Jialal, 2025. Type 2 Diabetes. StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing.

Lu X, Q Xie, X Pan et al. 2024. 'Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy', Signal Transduction and Targeted Therapy 9:262.

McGill JB, IB Hirsch, CG Parkin et al., 2024. 'The current and future role of insulin therapy in the management of type 2 diabetes: a narrative review', Diabetes Therapy, 15:1085-98.

Minari TP, LHB Tácito, LBT Yugaret al., 2023. 'Nutritional strategies for the management of type 2 diabetes mellitus: a narrative review', Nutrients 15:5096.

Ohiagu FO, PC Chikezie and CM Chikezie, 2021. Pathophysiology of diabetes mellitus complications: Metabolic events and control. Biomedical Research and Therapy 8:4243-57.

Prasetyo B, 2025. Type 2 Diabetes Mellitus: A Review of Determinants, Pathophysiology, Diagnostics, Management, and Complications. Journal of Scientific Research, Education, and Technology (JSRET) 4:1347-54.

Sanyaolu A, A Marinkovic, S Prakash et al., 2023. Diabetes mellitus: An overview of the types, prevalence, comorbidity, complication, genetics, economic implication, and treatment. World Journal of Meta-Analysis 11:134-43.

Singh N, R Kesherwani, AK Tiwari et al., 2016. A review on diabetes mellitus. The Pharma Innovation 5:36.

Tegegne BA, Adugna, Yenet et al., 2024. 'A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents', Frontiers in Endocrinology 15:1440456.

Vybhavi VJ, Bhavsar, Gusani et al. 2025. 'New insights into the pathophysiology of type 2 diabetes: a review article', Journal of Pharmacy and Bioallied Sciences 17:40655865.

Wu Q, J Zhang, F Zhang et al., 2025. SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes. Frontiers in Endocrinology 16:1601633.

Yameny AA, 2025. Diabetes Mellitus: A Comprehensive Review of Types, Pathophysiology, Complications, and Standards of Care in Diabetes 2025. Journal of Medical and Life Science 7:134-41.